Goldman Sachs initiates coverage on Carlsmed stock with Buy rating

Goldman Sachs has initiated coverage on Carlsmed Inc (CARL), a medical technology company specializing in AI-enabled customized spinal implants, with a Buy rating and a $19.00 price target, representing approximately 40% upside potential. The investment bank cited Carlsmed's differentiated technology, strong projected revenue growth, and an asset-light business model accelerating its path to profitability as key drivers. This positive initiation follows Carlsmed's recent IPO, which saw shares priced at $15, raising approximately $100.5 million.

Analysis

Goldman Sachs has initiated coverage on the recently-listed Carlsmed Inc. (CARL) with a 'Buy' rating and a $19.00 price target, signaling approximately 40% potential upside from its current trading price of $13.58. The positive outlook is underpinned by Carlsmed's differentiated position in the medical technology sector, driven by its Aprevo platform which uses AI and CT imaging to create patient-specific 3D-printed spinal implants. This technology aims to improve surgical outcomes and reduce long-term healthcare costs. The investment bank also highlighted the company's projected revenue growth trajectory and an asset-light business model as key factors accelerating its path to profitability. This analyst coverage follows Carlsmed's recent IPO on the Nasdaq, where it priced 6.7 million shares at $15.00 each to raise gross proceeds of approximately $100.5 million. Despite the bullish initiation, the stock is currently trading below its IPO price and its 52-week high of $15.20, while technical indicators like the RSI suggest the stock may be in overbought conditions.

Key Decisions for Investors

• Given the Goldman Sachs 'Buy' rating and a $19 price target, investors with a long-term growth focus could consider the current trading price below the $15 IPO level as a potential entry point for exposure to a differentiated med-tech innovator.
• Despite the strong fundamental thesis, traders should exercise caution regarding potential near-term volatility, as the Relative Strength Index (RSI) indicates the stock is in a technically overbought condition.
• As an emerging growth stage company, it is critical to monitor Carlsmed's execution on its revenue ramp-up and progress towards profitability, as these are the core pillars supporting the bullish analyst outlook.